Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Short-term outcomes associated with temozolomide vs. PCV chemotherapy for 1p/19q-codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation

Nayan Lamba, Malia McAvoy, Vasileios K. Kavouridis, Timothy R. Smith, Mehdi Touat, David A. Reardon, View ORCID ProfileJ. Bryan Iorgulescu
doi: https://doi.org/10.1101/2020.03.29.20046805
Nayan Lamba
1Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA
2Department of Medicine, Cambridge Health Alliance, Cambridge, MA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malia McAvoy
3Harvard Medical School, Boston, MA
4Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vasileios K. Kavouridis
4Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA
5Department of Surgery, St. Elizabeth’s Medical Center, Brighton, MA
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy R. Smith
3Harvard Medical School, Boston, MA
4Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA
M.D., Ph.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mehdi Touat
6Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA
7Sorbonne Université; Institut du Cerveau et de la Moelle épinière; Service de Neurologie, Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Reardon
3Harvard Medical School, Boston, MA
8Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Bryan Iorgulescu
3Harvard Medical School, Boston, MA
4Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA
9Department of Pathology, Brigham and Women’s Hospital, Boston, MA
10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Bryan Iorgulescu
  • For correspondence: jiorgulescu@bwh.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

PURPOSE The optimal chemotherapy regimen between temozolomide (TMZ) and procarbazine, lomustine, and vincristine (PCV) remains uncertain for newly-diagnosed anaplastic oligodendroglioma (AO). We therefore addressed this question using a national database.

METHODS Patients newly-diagnosed with 1p/19q-codeleted W.H.O. grade III AO between 2010-2016 were identified from the National Cancer Database. Predictors of receiving first-line single-agent TMZ vs. multi-agent PCV were assessed by multivariable logistic regression. Overall survival (OS) was estimated by Kaplan-Meier techniques and evaluated by multivariable Cox regression.

RESULTS 1,360 AO patients were identified: 74.5% (n=1,013) treated with TMZ, 9.6% (n=131) with PCV, and 15.9% (n=216) with no chemotherapy in the first-line setting. In multivariable logistic analysis, PCV utilization increased from 2010 to 2016 (OR=1.38/year, 95%CI: 1.22-1.56, p<0.001) and was less commonly utilized in privately insured patients (OR=0.38 vs. uninsured, 95%CI: 0.15-0.97, p=0.04). In survival analyses (33.1% reached endpoint), there was no difference in unadjusted OS between TMZ (5yr-OS 60.1%, 95%CI: 55.9-64.1) and PCV (5yr-OS 61.1%, 95%CI: 45.6-73.5; p=0.42). There remained no OS difference between TMZ and PCV in the 75.9% (n=1,032) of AO patients that also received radiotherapy (p=0.51), in the Cox regression analysis adjusted by age, extent of resection, and radiotherapy (TMZ vs. PCV HR=1.31, 95%CI: 0.83-2.08, p=0.24), and in subgroup analyses that incorporate KPS or MGMT status.

CONCLUSIONS In a national database of AOs managed in the ‘real-world’ setting, there is no difference in the short-term mortality between first-line TMZ and PCV chemotherapy. These findings provide preliminary data while we await the long-term results from the CODEL trial.

Competing Interest Statement

Declarations: The authors have no declarations. Funding: JBI is supported by an NIH 5T32HL007627 award. Conflicts of interest: The authors report no conflicts of interest.

Funding Statement

Funding: JBI is supported by an NIH 5T32HL007627 award.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • This work was presented in part at the 2019 annual meeting of the Society for Neuro-Oncology.

Data Availability

Availability of data and material: Data are publicly available by application to the American College of Surgeons in accordance with the National Cancer Database’s data use agreement. Code availability: Available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 01, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Short-term outcomes associated with temozolomide vs. PCV chemotherapy for 1p/19q-codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Short-term outcomes associated with temozolomide vs. PCV chemotherapy for 1p/19q-codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation
Nayan Lamba, Malia McAvoy, Vasileios K. Kavouridis, Timothy R. Smith, Mehdi Touat, David A. Reardon, J. Bryan Iorgulescu
medRxiv 2020.03.29.20046805; doi: https://doi.org/10.1101/2020.03.29.20046805
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Short-term outcomes associated with temozolomide vs. PCV chemotherapy for 1p/19q-codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation
Nayan Lamba, Malia McAvoy, Vasileios K. Kavouridis, Timothy R. Smith, Mehdi Touat, David A. Reardon, J. Bryan Iorgulescu
medRxiv 2020.03.29.20046805; doi: https://doi.org/10.1101/2020.03.29.20046805

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1744)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (649)
  • Epidemiology (10769)
  • Forensic Medicine (8)
  • Gastroenterology (582)
  • Genetic and Genomic Medicine (2927)
  • Geriatric Medicine (286)
  • Health Economics (530)
  • Health Informatics (1917)
  • Health Policy (832)
  • Health Systems and Quality Improvement (740)
  • Hematology (289)
  • HIV/AIDS (626)
  • Infectious Diseases (except HIV/AIDS) (12493)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (318)
  • Neurology (2777)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (596)
  • Oncology (1451)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (254)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (378)
  • Pediatrics (863)
  • Pharmacology and Therapeutics (361)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2625)
  • Public and Global Health (5331)
  • Radiology and Imaging (1001)
  • Rehabilitation Medicine and Physical Therapy (592)
  • Respiratory Medicine (721)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (124)